View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
Sponsored by Medidata

Direct-to-Patient Clinical Trials

Free White Paper

Direct-to-Patient Clinical Trials

By Medidata

Direct-to-Patient Clinical Trials

By Medidata
Enter your details to receive the free paper:

Drug development is a risky endeavour that is expensive, complex, and lengthy.

A significant portion of resources earmarked for drug development programmes are consumed by screening, recruiting, enrolling, engaging, monitoring, and retaining patients in clinical trials.

The pharmaceutical industry is continually exploring novel trial designs and methods that may alleviate the high costs and shorten study times, which can ultimately expedite new medicines to market. In clinical trials, the Direct-to-Patient (DtP) model allows for study medications to be received and administered in a patient’s home rather than a clinical site. The DtP drug supply model has gained momentum in recent years and continues to evolve since it can confer valuable benefits to sponsors and patients.

This white paper provides an overview of the factors that drive the rapidly evolving clinical trial design landscape and demonstrates how DtP trials can solve some of the difficulties facing drug sponsors today, including common pitfalls to consider when embarking on a DtP trial.

Download this white paper today.

Websites in our network
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
I consent to New Statesman Media Group collecting my details provided via this form in accordance with the Privacy Policy